Nothing Special   »   [go: up one dir, main page]

EA201690321A1 - Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей - Google Patents

Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей

Info

Publication number
EA201690321A1
EA201690321A1 EA201690321A EA201690321A EA201690321A1 EA 201690321 A1 EA201690321 A1 EA 201690321A1 EA 201690321 A EA201690321 A EA 201690321A EA 201690321 A EA201690321 A EA 201690321A EA 201690321 A1 EA201690321 A1 EA 201690321A1
Authority
EA
Eurasian Patent Office
Prior art keywords
muc1
treatment
maitanzinoid
immunocong
contract
Prior art date
Application number
EA201690321A
Other languages
English (en)
Inventor
Сильви Ассадуриан
Доминик Миньяр
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи filed Critical Санофи
Publication of EA201690321A1 publication Critical patent/EA201690321A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к конъюгату, содержащему (i) средство, связывающееся с клетками, которое связывается с гликопротеином муцином-1 человека (MUC1), соединенное (ii) по меньшей мере с одним цитотоксическим средством, для применения в лечении рака, где указанный конъюгат вводят в дозе, составляющей по меньшей мере 120 мг/м.
EA201690321A 2013-08-02 2014-07-30 Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей EA201690321A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13306119 2013-08-02
PCT/EP2014/066345 WO2015014879A1 (en) 2013-08-02 2014-07-30 Use of anti-muc1 maytansinoid immunoconjugate antibody for the treatment of solid tumors

Publications (1)

Publication Number Publication Date
EA201690321A1 true EA201690321A1 (ru) 2016-12-30

Family

ID=49036539

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690321A EA201690321A1 (ru) 2013-08-02 2014-07-30 Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей

Country Status (12)

Country Link
US (1) US20160347856A1 (ru)
EP (1) EP3027218A1 (ru)
JP (1) JP2016525560A (ru)
KR (1) KR20160035600A (ru)
CN (1) CN105592861A (ru)
AU (1) AU2014298514A1 (ru)
CA (1) CA2919932A1 (ru)
EA (1) EA201690321A1 (ru)
IL (1) IL243843A0 (ru)
MX (1) MX2016001541A (ru)
TW (1) TW201605479A (ru)
WO (1) WO2015014879A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016036861A1 (en) * 2014-09-02 2016-03-10 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
GB201506388D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W Site-specific antibody-drug conjugates
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
CN105997942B (zh) * 2016-06-24 2019-01-29 浙江大学 一种人血清白蛋白负载美登素类药物的纳米颗粒及其制备方法和应用
US11673966B2 (en) 2017-01-18 2023-06-13 Nanocruise Pharmaceutical Ltd. Monoclonal and humanized antibodies to a cancer glycopeptide
CA3072399A1 (en) * 2017-08-09 2019-02-14 Helmholtz-Zentrum Fur Infektionsforschung Gmbh New targeted cytotoxic ratjadone derivatives and conjugates thereof
SI3794042T1 (sl) * 2018-05-18 2024-07-31 Daiichi Sankyo Co., Ltd. Konjugat protitelesa anti-MUC1-exatecan in citotoksično sredstvo
US20220023439A1 (en) * 2018-11-02 2022-01-27 Cytomx Therapeutics, Inc. Activatable anti-cd166 antibodies and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010041337A (ko) * 1998-02-25 2001-05-15 마키타 키요아키 각막 상피 장애증 치료제
ATE496944T1 (de) * 2003-07-21 2011-02-15 Immunogen Inc Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung
WO2007024222A1 (en) * 2005-08-22 2007-03-01 Immunogen, Inc. A ca6 antigen-specific cytotoxic conjugate and methods of using the same
WO2010126552A1 (en) * 2009-04-30 2010-11-04 Immunogen, Inc. Potent cell-binding agent drug conjugates
WO2010126551A1 (en) * 2009-04-30 2010-11-04 Immunogen, Inc. Potent conjugates and hydrophilic linkers

Also Published As

Publication number Publication date
EP3027218A1 (en) 2016-06-08
MX2016001541A (es) 2016-08-18
US20160347856A1 (en) 2016-12-01
CA2919932A1 (en) 2015-02-05
JP2016525560A (ja) 2016-08-25
CN105592861A (zh) 2016-05-18
TW201605479A (zh) 2016-02-16
IL243843A0 (en) 2016-04-21
KR20160035600A (ko) 2016-03-31
AU2014298514A1 (en) 2016-03-10
WO2015014879A1 (en) 2015-02-05
WO2015014879A9 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
EA201690321A1 (ru) Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
EA201992590A1 (ru) Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения
EA201691023A1 (ru) Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
EP4276114A3 (en) Cd20 binding single domain antibodies
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
MX2022015748A (es) Uso de una molecula anti-b7-h3 en combinacion con una molecula anti-pd-1 en la preparacion de formulaciones para el tratamiento de cancer.
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
EA201690905A1 (ru) Специфические антитела против cd38 для лечения злокачественных новообразований у человека
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
UA115517C2 (uk) Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
UA110370C2 (en) Conjugates of amatoxin with improved linkages
BR112015021134A2 (pt) conjugados de fármaco e anticorpo
BR112015028244A2 (pt) Imunoconjugado que se liga ao folr1 e seu uso
PH12015500392A1 (en) Antibody drug conjugates (adc) that bind to 158p1d7 proteins
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
PH12016500214A1 (en) Antibody drug conjugates (adc) that bind to cd37 proteins
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
WO2017062615A3 (en) Combination therapy for the treatment of cancer
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof